SAN FRANCISCO, April 8, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the appointment of Charlotte Keywood, MD, as Chief Medical Officer of the Company’s therapeutics division. Dr. Keywood brings over 20 years of experience in the biopharmaceutical drug development industry, including the development of Parkinson’s disease Levadopa-Induced Dyskynesia (PD LID) drug candidates.
Help employers find you! Check out all the jobs and post your resume.
